Bakhrushina Elena O, Afonina Alina M, Mikhel Iosif B, Demina Natalia B, Plakhotnaya Olga N, Belyatskaya Anastasiya V, Krasnyuk Ivan I, Krasnyuk Ivan I
A.P. Nelyubin Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119048, Russia.
Polymers (Basel). 2024 Oct 21;16(20):2943. doi: 10.3390/polym16202943.
In recent years, stimulus-sensitive drug delivery systems have been developed for parenteral administration as a depot system. In situ systems incorporate smart polymers that undergo a phase transition at the site of administration. All parenteral and ocular dosage forms must meet sterility requirements. Careful selection of the sterilization method is required for any type of stimuli-sensitive system. Current sterilization methods are capable of altering the conformation of polymers or APIs to a certain extent, ultimately causing the loss of pharmacological and technological properties of the drug. Unfortunately, the issues of risk assessment and resolution regarding the sterilization of stimuli-sensitive systems, along with ways to stabilize such compositions, are insufficiently described in the scientific literature to date. This review provides recommendations and approaches, formulated on the basis of published experimental data, that allow the effective management of risks arising during the development of in situ systems requiring sterility.
近年来,已开发出用于肠胃外给药的刺激敏感型药物递送系统作为一种长效释放系统。原位系统包含在给药部位发生相变的智能聚合物。所有肠胃外和眼用剂型都必须满足无菌要求。对于任何类型的刺激敏感型系统,都需要仔细选择灭菌方法。目前的灭菌方法能够在一定程度上改变聚合物或活性药物成分的构象,最终导致药物的药理和技术性质丧失。遗憾的是,迄今为止,科学文献中对刺激敏感型系统灭菌的风险评估和解决问题以及稳定此类组合物的方法描述不足。本综述基于已发表的实验数据提出了建议和方法,可有效管理在需要无菌的原位系统开发过程中产生的风险。